75 patents
Page 3 of 4
Utility
Pharmaceutical Formulations Containing Gaboxadol for Therapeutic Treatment
21 Jan 21
Pharmaceutical formulations containing gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremors, Tourette syndrome or Fragile X syndrome are provided.
Matthew DURING
Filed: 15 Jul 20
Utility
Methods and Compositions for Treatment of Epileptic Disorders
6 Jan 21
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew DURING
Filed: 16 Sep 20
Utility
Use of MIR101 or MIR128 in the treatment of seizure disorders
21 Dec 20
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew During
Filed: 5 Dec 18
Utility
Use of Gaboxadol for the Treatment of Tourette Syndrome, Tics and Stuttering
2 Dec 20
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew DURING
Filed: 19 Aug 20
Utility
Use of MIR101 or MIR128 in the treatment of seizure disorders
16 Nov 20
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew During
Filed: 5 Dec 18
Utility
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
26 Oct 20
Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Matthew During, Brett Abrahams
Filed: 6 Jun 19
Utility
Use of Gaboxadol in the treatment of diabetes and related conditions
26 Oct 20
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease.
Matthew During
Filed: 1 Aug 18
Utility
Use of MIR-92A or MIR-145 In the Treatment of Angelman Syndrome
21 Oct 20
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome.
Matthew DURING
Filed: 6 Jul 20
Utility
Methods and compositions for treatment of epileptic disorders
12 Oct 20
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew During
Filed: 12 Feb 20
Utility
Methods of treating developmental encephalopathies
7 Sep 20
Methods of treating developmental encephalopathies by administering compositions including ketamine, norketamine, or other derivatives of ketamine, or a pharmaceutically acceptable salt of any of the foregoing, are provided.
Matthew During
Filed: 11 Apr 18
Utility
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
7 Sep 20
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew During
Filed: 19 Sep 19
Utility
Methods of treating developmental syndromes with PDE10A inhibitors
10 Aug 20
Methods of treating developmental syndromes with a PDE10A inhibitor are provided.
Matthew During
Filed: 14 Feb 19
Utility
Use of (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC Acid and (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC Acid In the Treatment of Tinnitus, Acute Sensorineural Hearing Loss, Meniere's Disease, Tourette's Syndrome, Attention Deficit Hyperactivity Disorder and Addiction
5 Aug 20
Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 16 Apr 20
Utility
Use of Gaboxadol In the Treatment of Narcolepsy
15 Jul 20
Methods and compositions for treating narcolepsy are provided which include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with narcolepsy.
Matthew DURING
Filed: 24 Mar 20
Utility
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
6 Jul 20
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome.
Matthew During
Filed: 13 Jun 19
Utility
Use of Gaboxadol for the Treatment of NON-24 Hour Sleep-wake Disorder
17 Jun 20
Treatment of non 24 sleep wake disorder using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew DURING
Filed: 16 Dec 19
Utility
Methods and Compositions for Treatment of Epileptic Disorders
10 Jun 20
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew DURING
Filed: 12 Feb 20
Utility
Treatment of Depressive Disorders
10 Jun 20
Formulations for treating depressive disorders and methods for treating depressive disorders using gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 18 Feb 20
Utility
Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
18 May 20
Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 7 Feb 19
Utility
Use of Gaboxadol, Ganaxolone and Allopregnanolone to Treat Movement Disorders
6 May 20
Use of gaboxadol, allopregnanolone, or ganaxolone, or a pharmaceutical salt of any of the foregoing, for the treatment of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in a subject in need thereof.
Matthew DURING
Filed: 4 Nov 19